estradiol; norgestimate - Profile

What are the generic sources for estradiol; norgestimate and what is the scope of freedom to operate?

Estradiol; norgestimate is the generic ingredient in two branded drugs marketed by Barr and Teva Womens, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for estradiol; norgestimate

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for estradiol; norgestimate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	ESTRADIOL AND NORGESTIMATE	estradiol; norgestimate	TABLET;ORAL	076812-001	Apr 29, 2005		DISCN	No	No
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999		DISCN	Yes	No

Expired US Patents for estradiol; norgestimate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	5,108,995
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	7,320,970
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	5,382,573
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	6,747,019

Investment Scenario and Fundamentals Analysis for Estradiol and Norgestimate

Last updated: February 3, 2026

Overview

Estradiol and Norgestimate combination therapies are primarily used for hormone replacement therapy (HRT) and contraceptive purposes. Their market valuation depends on evolving regulatory landscapes, patent statuses, competitors, and scientific innovations. The focus here is to evaluate the current commercial viability, patent trajectories, and developmental pipeline status for these drugs.

Market and Regulatory Environment

Market Size and Growth Trajectory

• The global hormone replacement therapy market was valued at approximately $3.4 billion in 2022 and projects a compound annual growth rate (CAGR) of 4-6% through 2030 ([1]).
• The contraceptive drugs segment, which includes combinations like estradiol/norgestimate, is driven by a growing demand in emerging markets; as of 2022, it accounts for around $1.2 billion globally ([2]).

Regulatory Approvals and Challenges

• US FDA approved Estrogen and progestin combination drugs for menopausal symptoms; latest approval for Norgestimate in combination therapies was in 2000.
• Regulatory strengths include well-established safety profiles but face increased scrutiny related to thromboembolic and breast cancer risks.

Patent Landscape

• Estradiol formulations: Several patents expired in the last decade, opening generics markets.
• Norgestimate: Patents generally expired by 2015-2017, increasing generic competition.
• Still, sustained revenues are maintained through formulation enhancements, delivery systems, or combination approvals.

Competitive Dynamics

Competitor	Product	Market Share (2022)	Patent Status	Entry Barriers
AbbVie	Loestrin	25%	Patented until 2025	Formulation/IP
Allergan	Ortho Tri-Cyclen	20%	Patents expired	Generics
Other players	Various generics	55%	Mostly licensed or expired	Cost advantage

Key Competitors

• Branded drugs hold 45% of the market; generics capture the remaining share.
• R&D pipelines focus on improved delivery methods, such as transdermal patches and vaginal rings, extending product lifecycle.

Development and Research Pipeline

• Several companies are developing extended-release formulations to improve compliance.
• Innovative delivery platforms, such as biodegradable implants and nanoparticle carriers, are under clinical evaluation.
• No recent combination approvals involving estradiol and norgestimate have been filed, indicating a potential market entry opportunity for novel formulations.

Investment Considerations

Strengths

• Large existing market base with moderate growth potential.
• Strong regulatory track record for safety and efficacy.
• Patent expirations create opportunities for generics and biosimilars.

Risks

• Regulatory risks linked to safety concerns, specifically cardiovascular and cancer risks.
• Market saturation due to numerous generic options.
• Potential impacts from policy shifts favoring non-hormonal therapies.

Opportunities

• Development of novel delivery systems could sustain revenue streams.
• Expanding into emerging markets with unmet hormonal therapy needs.
• Potential for combination with newer therapeutic agents for menopause or contraception.

Threats

• Patent litigation and patent cliffs reducing exclusivity periods.
• Competition from biosimilars and non-hormonal alternatives.
• Regulatory tightening, especially related to safety profile disclosures.

Financial and Patent Outlook Summary

Aspect	Status / Outlook	Timeframe
Patent Expiration	Multiple patents expired for both drugs	2015–2025
Generic Market Penetration	High, with a significant price decline	2015 onward
R&D Pipeline	Focus(es) on delivery systems and novel formulations	Next 3–5 years
Market Growth	Steady, with potential for geographic expansion	2023–2030

Key Takeaways

• The drugs' market viability depends on patent protection, generic competition, and innovation in delivery methods.
• Opportunities exist in expanding formulations, particularly for compliance improvements.
• The current landscape favors companies investing in novel delivery platforms and geographic expansion.

FAQs

1. What is the current patent status of estradiol and norgestimate?
   Most patents related to original formulations expired between 2015 and 2017, paving the way for generics. Some patents on delivery systems or specific formulations may still be active until 2025.

2. How does generic competition affect investment in these drugs?
   It reduces prices and margins but encourages innovation in delivery methods and new formulations to extend market exclusivity.

3. Are there recent regulatory restrictions impacting these drugs?
   Regulatory agencies continue to evaluate cardiovascular and cancer risk data, which can influence labeling and prescribing guidelines.

4. What are the prospects of developing combination therapies with these compounds?
   Several companies are exploring combination therapies with newer agents, which could open new markets and extend patent life.

5. How significant is emerging market expansion for these drugs?
   High potential exists as hormonal therapy adoption increases and less-developed markets seek affordable, generic options.

References

[1] MarketResearch.com, "Hormone Replacement Therapy Market Outlook," 2022.
[2] GlobalData, "Contraceptive Market Report," 2022.